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The authors would like to correct errors that have recently been identified in our article published in September 2013.
In Figure 3A, the immunoblot for Perk following shATF6 knockdown was accidentally misaligned, showing results for shATF6 #2 and
#3 instead of shATF6 #1 and #2. The involved bands are similar in appearance. A correct version of Figure 3 is presented below.
Irrelevant lanes were removed in the construction of Figures 5E and S5C, but inadvertently this was not highlighted. In addition, in
both figures, post-treatment Gapdh controls were incorrectly shown for both pre- and post-treatment time points. The Gapdh con-
trols for these time points were similar. A correct version of Figure 5 is shown below, and a correct version of Figure S5C is included in
the online Supplemental Information. The experiment was repeated, yielding similar results.
These corrections do not affect the interpretation of the relevant results or the conclusions. The authors apologize for any confusion
that these errors may have caused.Figure 3. Only Ire1 among ER Stress Transducers Regulates BTZ Sensitivity in MM
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Figure 5. Ire1-Xbp1 Suppression and BTZ Resistance in MM Are Associated with De-Commitment to Plasma Cell Differentiation542 Cancer Cell 28, 541–543, October 12, 2015 ª2015 Elsevier Inc.
